-
TAK-220
- names:
TAK-220
- CAS号:
333994-00-6
MDL Number: - MF(分子式): C31H41ClN4O3 MW(分子量): 553.14
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000650-5mg | 5mg | 99.95% | ¥ 4725.00 | ¥ 4725.00 | 2-3天 | ¥ 0.00 | ||
| YZM000650-1mg | 1mg | 99.95% | ¥ 1950.00 | ¥ 1950.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 333994-00-6 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C31H41ClN4O3 |
| 分子量 Molecular Weight | 553.14 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度≥ 50 mg/mL(90.39 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
TAK-220(CAS:333994-00-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | TAK-220 是一种有效的选择性的,可口服的CCR5拮抗剂,能够抑制 RANTES,MIP-1α 与 CCR5 结合,IC50值分别为 3.5 nM 和 1.4 nM,但为对 CCR1,CCR2b,CCR3,CCR4 或者 CCR7 无作用; TAK-220 也可选择性地抑制HIV-1,在外周单核细胞中,EC50值分别为 1.2 nM (HIV-1 KK),0.72 nM (HIV-1 CTV),1.7 nM (HIV-1 HKW),1.7 nM (HIV-1 HNK),0.93 nM (HIV-1 HTN) 和 0.55 nM (HIV-1 HHA),EC90值分别为 12 nM (HIV-1 KK),5 nM (HIV-1 CTV),12 nM (HIV-1 HKW),28 nM (HIV-1 HNK),15 nM (HIV-1 HTN) 及 4 nM (HIV-1 HHA) |
| Introduction | TAK20 is a selective and orally bioavailableCCR5antagonist, withIC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIPα to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK20 also selectively inhibitsHIV, withEC50s of 1.2 nM (HIV KK), 0.72 nM (HIV CTV), 1.7 nM (HIV HKW), 1.7 nM (HIV HNK), 0.93 nM (HIV HTN), and 0.55 nM (HIV HHA), andEC90s of 12 nM (HIV KK), 5 nM (HIV CTV), 12 nM (HIV HKW), 28 nM (HIV HNK), 15 nM (HIV HTN), and 4 nM (HIV HHA) in PBMCs. |
| Application1 | |
| Application2 | |
| Application3 |
TAK-220 是一种有效的选择性的,可口服的CCR5拮抗剂,能够抑制 RANTES,MIP-1α 与 CCR5 结合,IC50值分别为 3.5 nM 和 1.4 nM,但为对 CCR1,CCR2b,CCR3,CCR4 或者 CCR7 无作用; TAK-220 也可选择性地抑制HIV-1,在外周单核细胞中,EC50值分别为 1.2 nM (HIV-1 KK),0.72 nM (HIV-1 CTV),1.7 nM (HIV-1 HKW),1.7 nM (HIV-1 HNK),0.93 nM (HIV-1 HTN) 和 0.55 nM (HIV-1 HHA),EC90值分别为 12 nM (HIV-1 KK),5 nM (HIV-1 CTV),12 nM (HIV-1 HKW),28 nM (HIV-1 HNK),15 nM (HIV-1 HTN) 及 4 nM (HIV-1 HHA)。TAK-220 is a selective and orally bioavailableCCR5antagonist, withIC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibitsHIV-1, withEC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), andEC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.
【1】.Takashima K, et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82.
【2】.Tremblay CL, et al. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5.
【2】.Tremblay CL, et al. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


